Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tezepelumab + topical corticosteroids
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous (tezepelumab), Inhalation (topical Corticosteroids)
01
Overview
**Tezepelumab + topical corticosteroids** is a therapeutic regimen for severe asthma consisting of tezepelumab, a human monoclonal antibody, and inhaled (topical) corticosteroids. **Tezepelumab** targets and inhibits thymic stromal lymphopoietin (TSLP), disrupting a key upstream cytokine in airway inflammation and thereby reducing asthma exacerbations across phenotypes. Topical (inhaled) corticosteroids act locally in the airways to suppress inflammation by modulating multiple immune pathways, reducing the frequency and severity of asthma attacks when used daily. This combination is intended for maintenance therapy in adolescents and adults with severe asthma uncontrolled by corticosteroids alone[1][3][5][7].
- Brand names
- Tezspire (for tezepelumab)varies by specific corticosteroid (e.g., Qvar, Pulmicort, Flovent, Asmanex)
- Other names
- tezepelumab plus topical corticosteroidstezepelumab plus inhaled corticosteroidstezepelumab + ICS
02
Targets
GR (Glucocorticoid receptor)TSLP (Thymic stromal lymphopoietin)
Beyond the preview
Go deeper on tezepelumab + topical corticosteroids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tezepelumab + topical corticosteroids.